Anal incontinence – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 13 Jun 2026 04:03:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Anal incontinence – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on ICEF15 for Treating Fecal Incontinence in Patients with Anal Sphincter Dysfunction https://clinicaltrials.eu/trial/study-on-icef15-for-treating-fecal-incontinence-in-patients-with-anal-sphincter-dysfunction/ Wed, 29 Apr 2026 15:03:26 +0000 https://clinicaltrials.eu/trial/study-on-icef15-for-treating-fecal-incontinence-in-patients-with-anal-sphincter-dysfunction/ This clinical trial is focused on studying a condition known as fecal incontinence, which affects both men and women. Fecal incontinence is when a person has difficulty controlling their bowel movements, leading to unexpected leakage. The study is testing a new treatment called ICEF15, which involves using special cells taken from a patient’s own muscles, known as autologous Skeletal Derived Muscle Cells (aSDMC). These cells are injected into the muscles to help improve control over bowel movements.

The purpose of the study is to evaluate how effective and safe the ICEF15 treatment is for people with fecal incontinence caused by problems with the external anal sphincter, a muscle that helps control bowel movements. Participants in the study will receive either the ICEF15 treatment or a placebo, which is a solution that does not contain the active treatment. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will receive injections and will be monitored over a period of time to see if there is a reduction in the frequency of incontinence episodes. The study aims to determine if the treatment can reduce these episodes by at least 50% compared to before the treatment started. This research is important for finding new ways to help people manage fecal incontinence and improve their quality of life.

]]> Study on the Safety and Effectiveness of Allogeneic Adipose-Derived Adult Mesenchymal Stem Cells for Treating Fecal Incontinence in Patients https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-allogeneic-adipose-derived-adult-mesenchymal-stem-cells-for-treating-fecal-incontinence-in-patients/ Wed, 29 Apr 2026 15:03:06 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-allogeneic-adipose-derived-adult-mesenchymal-stem-cells-for-treating-fecal-incontinence-in-patients/ This clinical trial is focused on studying a condition known as fecal incontinence, which is the inability to control bowel movements, leading to unexpected stool leakage. The study is testing a new treatment using allogeneic adipose-derived adult mesenchymal stem cells, which are special cells taken from fat tissue and expanded in a lab. These cells are then prepared in a gel made from hyaluronic acid, a substance that helps with tissue repair, and are injected directly into the affected area.

The purpose of the study is to evaluate the safety and effectiveness of this treatment. Participants will receive one of two different doses of the stem cells, or a placebo, to determine which dose works best. The study will monitor participants over a period of time to see how well the treatment improves their condition. This includes checking for any side effects and measuring changes in the severity of their incontinence using tests like the Jorge-Wexner test, which scores the degree of incontinence from 0 (no incontinence) to 20 (severe incontinence).

Throughout the study, participants will also keep a diary to record episodes of incontinence and complete a quality of life survey. Additional tests, such as anal manometry, which measures the pressure in the anal canal, will be conducted to assess any changes in the function of the anal muscles. The study aims to provide valuable information on whether this new cell-based treatment can offer a better quality of life for those suffering from fecal incontinence.

]]> Study on the Effects of Botulinum Toxin Type A and a Drug Combination on Rectal Function in Patients with Fecal Incontinence https://clinicaltrials.eu/trial/study-on-the-effects-of-botulinum-toxin-type-a-and-a-drug-combination-on-rectal-function-in-patients-with-fecal-incontinence/ Wed, 29 Apr 2026 15:01:40 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-botulinum-toxin-type-a-and-a-drug-combination-on-rectal-function-in-patients-with-fecal-incontinence/ This clinical trial is focused on studying the effects of a treatment for fecal incontinence, a condition where individuals have difficulty controlling their bowel movements. The treatment being investigated involves injections of botulinum toxin type A, commonly known as Botox, directly into the rectum. The purpose of the study is to understand how these injections affect the movement and function of the rectum, particularly when stimulated by laxatives.

Participants in the study will receive the botulinum toxin injections and will be monitored over a period of one month. During this time, researchers will observe changes in rectal movement using a technique called high-resolution manometry, which measures pressure inside the rectum. The study will also involve the use of laxatives such as MOVIPREP and DULCOLAX to stimulate bowel movements and assess the treatment’s impact on rectal motility.

Throughout the study, various aspects will be evaluated, including the number and strength of contractions in the rectum, the time it takes for these contractions to occur, and any changes in the participants’ quality of life. The study will also monitor any side effects that may arise from the treatment. The goal is to gather valuable information that could lead to improved treatments for individuals suffering from fecal incontinence.

]]>